Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides
This patent covers technology developed by Tevogen.AI that leverages machine learning algorithms, powered by Microsoft (Nasdaq: MSFT) and Databricks intended to rapidly and accurately identify peptides with strong immune system interactions. Identifying these peptides is critical in developing targeted therapies for a variety of diseases, including cancers and infectious diseases.
Traditional methods for identifying immunologically active peptides often face significant limitations, such as overlooking critical human genetic diversity factors like age, sex, race, and ethnicity. Tevogen.AI's proprietary approach may overcome these challenges by: Efficiently screening and ranking potential peptides based on their immunological activity.
Eliminating peptides likely to be ineffective due to self-tolerance or human genome overlap.
Continuously refining predictions using real-world data to train and enhance machine learning models.
'I'm pleased with Tevogen.AI's continued progress in strategically harnessing artificial intelligence in support of our cell therapy development,' said Dr. Ryan Saadi, Founder and CEO of Tevogen. 'Leveraging AI to accelerate discovery, shorten development timelines, and reduce costs is essential to our mission of delivering commercially attractive, economically viable, and cost-effective personalized T cell therapies.'
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen's plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as 'may,' 'could,' 'would,' 'expect,' 'anticipate,' 'possible,' 'potential,' 'goal,' 'opportunity,' 'project,' 'believe,' 'future,' and similar words and expressions or their opposites. These statements are based on management's expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen's business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen's limited operating history; and those factors discussed or incorporated by reference in Tevogen's Annual Report on Form 10-K.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
[email protected]
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
SIMPPLE Ltd. Fully Regains Compliance with Nasdaq's Continued Listing Requirements
Singapore, July 24, 2025 (GLOBE NEWSWIRE) -- SIMPPLE Ltd. (NASDAQ: SPPL) ('SIMPPLE' or 'the Company'), a leading technology provider and innovator in the facilities management (FM) sector, today announced that it has received notice from The Nasdaq Stock Market LLC ('Nasdaq') notifying the Company that the Company has regained compliance with the Nasdaq Capital Market's minimum stockholders' equity requirement and annual shareholder meeting requirement, as required by Nasdaq Listing Rules. As previously reported in the Company's Form 6-K dated January 21, 2025, the Company did not comply with the minimum stockholders' equity of $2,500,000 as required for continued listing on Nasdaq set forth in Nasdaq Listing Rule 5550(b)(1). The Company has since filed a Form 6-K dated July 7, 2025, stating that the Company had executed a series of securities purchase agreements with investors to raise aggregate gross proceeds of $2.0 million resulting from the sale of 1,333,334 shares through a private investment in public equity (PIPE). As a result of the closing of the private placement on June 30, 2025, the Company's shareholders' equity exceeded $2.5 million. SIMPPLE intends to use the net proceeds from the PIPE to advance development of its technologies, extensive pipeline, and global expansion. On July 22, 2025, Nasdaq notified the Company that the Company complies with the Listing Rule 5550(b)(1), subject to the Company's disclosure in a Form 6-K no later than July 25, 2025, providing a description of the completed transaction or event that enabled the Company to satisfy the stockholders' equity requirement for continued listing. Nasdaq will continue to monitor the Company's ongoing compliance with the stockholders' equity requirement and, if at the time of its next periodic report, the Company does not evidence compliance, it may be subject to delisting. At that time, Staff will provide written notification to the Company, which may then appeal Staff's determination to a Hearings Panel. 'We are pleased to have successfully regained compliance with Nasdaq's continued listing requirements and consider this latest notification a key milestone that underscores our broader business objectives' said Norman Schroeder, SIMIPPLE's chief executive. 'We believe it's an important outcome that goes to SIMPPLE's credibility, and best interest of our valued investors, partners, and stakeholders, as we continue to invest in our technology advancements and global growth objectives.' The Company will continue to monitor its ongoing compliance with all applicable Nasdaq listing standards and will provide further updates as and when required. About SIMPPLE LTD. Headquartered in Singapore, SIMPPLE LTD. is an advanced technology solution provider in the emerging PropTech space, focused on helping facilities owners and managers manage facilities autonomously. Founded in 2016, the Company has a strong foothold in the Singapore facilities management market, serving over 60 clients in both the public and private sectors and extending out of Singapore into Australia and the Middle East. The Company has developed its proprietary SIMPPLE Ecosystem, to create an automated workforce management tool for building maintenance, surveillance and cleaning comprised of a mix of software and hardware solutions such as robotics (both cleaning and security) and Internet-of-Things ("IoT") devices. For more information on SIMPPLE, please visit: Safe Harbor Statement This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as 'may,' 'should,' 'expects,' 'anticipates,' 'contemplates,' 'estimates,' 'believes,' 'plans,' 'projected,' 'predicts,' 'potential,' or 'hopes' or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur. CONTACT: For investor and media queries, please contact: SIMPPLE LTD. Investor Relations Department Email: ir@
Hamilton Spectator
36 minutes ago
- Hamilton Spectator
Cannabix Technologies Annual General and Special Meeting Results
VANCOUVER, British Columbia, July 24, 2025 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the 'Company') announces the results of its annual general and special meeting of common shareholders held on July 24, 2025 in Vancouver. Resolutions passed at the meeting included the appointment of SHIM and Associates LLP as auditors for the ensuing year, and the election of five directors: Dr. Raj Attariwala, Dr. Phillip Olla, Ravinder Mlait, Bryan Loree, and William Corl. We seek Safe Harbor. On behalf of the Board of Directors 'Rav Mlait' CEO Cannabix Technologies Inc. For further information, contact the Company at info@ The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Yahoo
an hour ago
- Yahoo
3 Dirt Cheap Stocks to Buy With $1,000 Right Now
Key Points ASML Holdings recently pulled back, but its technology monopoly is intact. Booz Allen Hamilton has been the victim of DOGE cuts but is still a crucial partner for mission-critical defense and intelligence work. Kulicke & Soffa has been forgotten but could be on the brink of recovery. 10 stocks we like better than ASML › The market has soared to new all-time highs in a miraculous recovery from the April 2 "Liberation Day" tariff scare. That being said, the market certainly isn't out of the tariff woods, so to speak, and valuations have now rerated much higher than a mere three months ago. That doesn't leave many "bargains" left in the market. However, the following three stocks have actually lagged the market's recovery because of unique company-specific circumstances. Yet each looks like a bargain at the moment from a longer-term perspective -- especially by today's valuation standards. ASML Holdings Semiconductor equipment giant ASML Holdings (NASDAQ: ASML) might not look "cheap" on the surface, but the stock is actually much cheaper than its recent history. In fact, at around 26 times earnings, the stock is now cheaper than it has been at any time over the past 10 years on a P/E basis except late 2018, just before extreme ultraviolent lithography (EUV) machine sales kicked off in earnest. ASML has traded relatively expensively because it has a monopoly on that critical EUV technology, which is needed to make semiconductor chips with transistors 7nm apart and below. Those types of chips were first produced back in the 2019 time-frame, while the chip industry is currently producing 3nm chips and on its way to 2nm chips later this year or early next year. But while ASML has typically traded at a premium, its valuation has fallen back relatively in line with other semicap equipment names. The most recent downturn in the stock happened this month after Q2 earnings, in which management withdrew guidance for 2026 being a "growth" year, because of tariff-related uncertainty in non-AI markets. While management still projects a strong 15% growth this year, the prospect of a slowdown or decline in 2026 clearly spooked investors, sending the stock down some 15% from recent pre-earnings levels. However, management didn't flag any decline in AI-related tailwinds, nor did it change its longer-term 2030 outlook for revenue between $44 billion and $60 billion, with gross margins between 56% and 60%. That compares with 2025 expectations of $32.2 billion in revenue and gross margins of just 52%. While current tariff and geopolitical controversies may be causing a near-term pause or conservatism on the part of ASML's customers, it shouldn't make much of a difference in the stock's intrinsic value, as long as ASML's competitive advantages and AI-related growth tailwinds remain intact. As of now, those more important factors seem like they're holding strong. Booz Allen Hamilton Consulting firm Booz Allen Hamilton (NYSE: BAH) remains more than 40% off its highs from last fall, on fears over the government's cost-cutting efforts. Booz Allen has become somewhat of an auspicious name in 2025, as the company essentially garners 100% of its business from the U.S. government. As such, investors have fled the stock because the company is the poster child for Department of Government Efficiency (DOGE) cuts. However, Booz Allen is mostly involved in mission-critical, high-tech initiatives for the defense, space, and intelligence services, which encompass 65% of its revenue. That portion of the business is not only high-growth but should also be resistant to too much government austerity. The other 35% of Booz's business is in civil services, and that is where recent DOGE cuts will hurt this year. On its last earnings conference call, Booz Allen management said it anticipates a low double-digit decline in the civil business this year in a one-time "reset." Yet management still forecasts 0% to 4% growth for the whole company for the fiscal year, as the defense/intelligence segment continues to implement next-gen AI solutions into the government's arsenal. And if the civil business stabilizes next year, Booz Allen could see a reacceleration off of this new "base." If that's the case, then Booz Allen's current below-market multiple of just 15 times trailing earnings seems way too cheap. Booz also isn't pulling back from seeking out new tech-forward growth initiatives. The company recently committed $300 million to its Booz Allen Ventures portfolio, which invests in revolutionary defense and cyber-oriented tech startups. That's an increase from the prior $100 million commitment. Management believes it will invest in 20 to 25 new young companies over the next few years. If just one turns out to be a "home run" investment, that could make a big difference in this $14 billion stock, trading at its cheapest valuation in years. Kulicke & Soffa Technology chip packaging leader Kulcike & Soffa (NASDAQ: KLIC) has had a really rough run over the past year or so. After booming in the pandemic period, the company's core ball bonder business has been mired in a post-pandemic funk, as PCs, smartphones, and the auto industry all suffered from severe hangovers. In addition, the company recently had to terminate and write off two significant projects. In 2024, K&S wrote off over $100 million from its advanced display business, after a large customer – supposedly, Apple -- ended its microLED initiative, to which K&S had invested resources. Then in May, K&S announced it would be winding down its money-losing electronics assembly business, resulting in yet another write-off of $87 million. While these wind-downs are unfortunate, neither were in K&S' core chip packaging business, where K&S dominates. On that note, there was actually some positive commentary last quarter. After a long three-year digestion period, K&S management noted utilization of their tools in Taiwan and China -- where most non-auto electronics are assembled -- had reached 80% or more. That's about the rate at which one would expect customers to begin ordering more tools in earnest. But K&S said that customers are holding off because of tariff-related fears. Still, they can only do so for so long if demand holds up. Given that this downcycle has been longer than the typical down-cycle, a strong recovery could be in the making. Additionally, K&S also has a small but growing business in thermocompression bonding (TCB), which can be used in artificial intelligence logic and high-bandwidth memory advanced packaging. That business is expected to reach about $70 million this year, or just over 10% of this year's expected revenue. But management sees this growing fast on the back of AI demand to over $100 million in fiscal 2026, good for about 50% growth. AI-related tailwinds in TCB combined with a recovery in the core ball bonding business could lead to significant upside, given that K&S stock is still a far 53% off its all-time highs. Should you buy stock in ASML right now? Before you buy stock in ASML, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and ASML wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $641,800!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,023,813!* Now, it's worth noting Stock Advisor's total average return is 1,034% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Billy Duberstein and/or his clients have positions in ASML, Apple, Booz Allen Hamilton, and Kulicke And Soffa Industries and has the following options: short December 2025 $55 puts on Booz Allen Hamilton. The Motley Fool has positions in and recommends ASML and Apple. The Motley Fool recommends Booz Allen Hamilton. The Motley Fool has a disclosure policy. 3 Dirt Cheap Stocks to Buy With $1,000 Right Now was originally published by The Motley Fool Sign in to access your portfolio
